- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07762326
Effect of Artificial Intelligence Based Cognitive Training on Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis (AI)
8 augustus 2026 bijgewerkt door: Rania Hamed Rashad Ahmed, Cairo University
this study will be conducted to investigate the effect of artificial intelligence (AI) based cognitive training on sleep disorders and quality of life in patients with multiple sclerosis.
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Multiple sclerosis (MS) is a chronic progressive inflammatory autoimmune neurodegenerative disease of central nervous system (CNS) and it is considered to be the most prevalent neurological disability of young adults, often leads to severe physical or cognitive incapacitation.
The severity of disability in MS patients is increased not only by motor disorders and other neurological deficit, but by the presence of cognitive impairment (CI), psycho-emotional disorders, like anxiety and/or depression, and sleep disorders (SD).
Cognitive dysfunction is one of the most common and consequential symptoms of MS.
Impairments in processing speed, working memory, learning, executive function, visuospatial processing, and language function affect an estimated 42% to70% of individuals with MS, and constitute a major cause of loss of employment and reduced quality of life.
Despite its high prevalence and effect, there are no definitive treatments for cognitive dysfunction in MS, and the identification of appropriate strategies to improve cognition in MS is hindered by a poor understanding of modifiable factors that may influence its severity.
AI is playing a significant role in harnessing neuroplasticity for cognitive enhancement through innovative applications such as cognitive training programs.These programs, driven by machine learning algorithms, can adapt to individual user performance, providing personalized training that optimizes cognitive functions such as memory, attention, and problem-solving .
Studietype
Ingrijpend
Inschrijving (Geschat)
40
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: rania hamed, master
- Telefoonnummer: 01112084518
- E-mail: Raniahamed542@gmail.com
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Nee
Beschrijving
Inclusion Criteria:
- Patient's age ranges from 25-40 years.
- Patient with EDSS not more than 5.
- Patients who have no relapses for the previous three months.
- Patients with sufficient cognitive abilities that enables them to understand and follow
- instructions with a score more than 24 according to the Mini-Mental State Examination scale
Exclusion Criteria:
- Mechanical or neuromascular problems.
- Cardiovascular problems (unstable angina, recent myocardial infarction within the last three months, congestive heart failure, significant heart valve dysfunction, or unstable hypertension) or pulmonary disorders.
- Auditory problems.
- Sensory impairment caused by other diseases except the MS such as diabetes mellitus.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: cognitive Therapy by artificial intillegence
Twenty patients with multiple sclerosis will receive a cognitive therapy by Lumosity application in addition to a designed physical-therapy program 3 times per week for 8 weeks
|
The patients will receive cognitive therapy by an artificial intelligence application called Lumosity.
Lumosity is an online cognitive training that can incredibly engage the individual's innate neuroplasticity, making the person smarter.
Perhaps Lumosity training actually increases the release of dopamine, the neurochemical that is very crucial for many brain functions, and the puls-designed physical therapy program
Patients will receive designed physical-therapy program in the form of sleep and bedtime restrictions, stimulus control instructions, education for sleep and promoting good sleep habits (or sleep hygiene), teaching relaxation skills
|
|
Actieve vergelijker: designed physical-therapy program
Twenty patients with multiple sclerosis will receive a designed physical-therapy program 3 times per week for 8 weeks)
|
Patients will receive designed physical-therapy program in the form of sleep and bedtime restrictions, stimulus control instructions, education for sleep and promoting good sleep habits (or sleep hygiene), teaching relaxation skills
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
sleep disability
Tijdsspanne: up to eight weeks
|
Pittsburgh Sleep Quality Index will be used to assess sleep disability. it gives impression on sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction over one month, The sum of scores for these seven components yields one global score.
Scoring of the answers is based on a 0 to 3 scale and a global sum equal or larger than 5 indicates a "poor" sleeper
|
up to eight weeks
|
|
daytime sleepiness
Tijdsspanne: up to eight weeks
|
Epworth Sleepiness Scale will be used to assess daytime sleepiness.
It measures the general level of daytime sleepiness it is composed of 8 items to rate on a 4 -point scale (0-3).
A higher score indicates higher level of daytime sleepiness.
Using a cut-off score > 10, it is possible to identify individuals with excessive daytime sleepiness.
Scores >16 indicates ever sleepiness
|
up to eight weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
cognitive disability
Tijdsspanne: up to eight weeks
|
CogniFit will be used to assess cognitive function.
it is a digital health platform offering computerized cognitive assessments and interventions for users, researchers, and practitioners.
The CogniFit cognitive score is an aggregate measure of your brain's performance across 20 more different cognitive skills.
The scale ranges from a minimum of 0 to a maximum of 800, evaluated against normalized data matched to your specific age and gender.
0 - 200 (Red): Below average for your age and sex; highlights a cognitive weakness.
200 - 400 (Yellow): Low range, but still within the normal average and open to improvement.
400-600 (Green): High score within the average; indicates good condition relative to peers.600-800
(Green): Above average; signals a distinct cognitive strength or skil.
|
up to eight weeks
|
|
oxygen saturation
Tijdsspanne: up to eight weeks
|
A smartwatch will be used to assess oxygen saturation.
|
up to eight weeks
|
|
heart rate
Tijdsspanne: up to eight weeks
|
A smartwatch will be used to assess heart rate
|
up to eight weeks
|
|
life disability
Tijdsspanne: up to eight weeks
|
World Health Organization Quality of Life Assessment Brief will be used to assess life disability.
it has a four-domain structure which are physical health, psychological domain, social domain and environmental domain to provide a short-form quality of life assessment.
Subjects rated all items on a 5-point Likert-type scale.
Raw scores for the domains of WHOQOL-BREF were calculated by adding values of single items and were transformed on the scale ranging from 0 to 100 where 100 is the highest and 0 the lowest.
|
up to eight weeks
|
|
fatigue severity
Tijdsspanne: up to eight weeks
|
The fatigue severity scale FSS will be used to assess fatigue severity.
it is a self-report scale with nine items that assess the degree of physical fatigue over the previous week.
The Fatigue Severity Scale (FSS) is scored by adding the answers to 9 questions and finding the total sum or the average mean.
Each question uses a 7-point scale from 1 (strongly disagree) to 7 (strongly agree) based on the past week.
Add all 9 numbers together.
The total score ranges from 9 to 63.Divide the total sum by 9.
The average score ranges from 1.0 to 7.0.a
higher score indicates more severity
|
up to eight weeks
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
20 augustus 2026
Primaire voltooiing (Geschat)
30 maart 2027
Studie voltooiing (Geschat)
30 maart 2027
Studieregistratiedata
Eerst ingediend
5 augustus 2026
Eerst ingediend dat voldeed aan de QC-criteria
8 augustus 2026
Eerst geplaatst (Werkelijk)
13 augustus 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
13 augustus 2026
Laatste update ingediend die voldeed aan QC-criteria
8 augustus 2026
Laatst geverifieerd
1 augustus 2026
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Auto-immuunziekten
- Ziekten van het immuunsysteem
- Demyeliniserende auto-immuunziekten, CZS
- Auto-immuunziekten van het zenuwstelsel
- Demyeliniserende ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Multiple sclerose
- Slaap-waakstoornissen
Andere studie-ID-nummers
- P.T.REC/012/006521
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .